Precigen (NASDAQ:PGEN) Price Target Raised to $10.00

Precigen (NASDAQ:PGEN) had its price target increased by HC Wainwright from $9.00 to $10.00 in a report published on Thursday morning,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Precigen’s Q3 2026 earnings at $0.00 EPS, FY2027 earnings at $0.22 EPS, FY2028 earnings at $0.44 EPS, FY2029 earnings at $0.69 EPS and FY2030 earnings at $1.02 EPS.

Other analysts have also recently issued research reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Precigen in a report on Thursday, January 22nd. Zacks Research raised shares of Precigen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 10th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Precigen has a consensus rating of “Hold” and a consensus price target of $9.50.

Precigen Price Performance

PGEN stock opened at $3.67 on Thursday. The stock has a market capitalization of $1.30 billion, a price-to-earnings ratio of -2.74 and a beta of 1.10. The company has a quick ratio of 3.95, a current ratio of 3.09 and a debt-to-equity ratio of 4.46. Precigen has a 52-week low of $1.11 and a 52-week high of $5.47. The stock’s fifty day simple moving average is $4.08 and its 200-day simple moving average is $3.97.

Precigen (NASDAQ:PGEN) last released its earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.09. Precigen had a positive return on equity of 2,317.96% and a negative net margin of 2,588.21%.The firm had revenue of $4.57 million during the quarter, compared to analyst estimates of $8.29 million. Equities research analysts expect that Precigen will post -0.32 EPS for the current year.

Institutional Investors Weigh In On Precigen

Several large investors have recently made changes to their positions in PGEN. Investment Insight Wealth Management LLC acquired a new position in shares of Precigen during the 4th quarter valued at $443,000. Invesco Ltd. increased its holdings in Precigen by 250.8% in the 4th quarter. Invesco Ltd. now owns 373,782 shares of the biotechnology company’s stock valued at $1,562,000 after purchasing an additional 267,223 shares in the last quarter. NewEdge Advisors LLC purchased a new position in Precigen in the fourth quarter valued at about $45,000. XTX Topco Ltd raised its position in Precigen by 25.2% in the fourth quarter. XTX Topco Ltd now owns 49,668 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 10,005 shares during the period. Finally, VARCOV Co. acquired a new position in shares of Precigen during the fourth quarter worth about $224,000. Institutional investors and hedge funds own 33.51% of the company’s stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised multi‑year EPS forecasts (Q3‑2026 to FY2030) and reiterated a Buy rating with a $10 price target, projecting material earnings improvement through 2030 — supportive for longer‑term upside.
• Positive Sentiment: Citizens/JMP lifted its price target to $9 and moved to “market outperform,” adding another near‑term bullish analyst signal. Benzinga coverage
• Positive Sentiment: Management says PAPZIMEOS launch is accelerating with broad U.S. payer coverage and expects Q1 revenue to exceed $18M; company guidance points toward cash‑flow breakeven in 2026 if momentum continues. Precigen expects Q1 revenue to exceed $18M as PAPZIMEOS launch accelerates…
• Positive Sentiment: Analyst write‑ups highlight PAPZIMEOS’s blockbuster potential and model scenarios that imply meaningful upside from current levels, underpinning buy‑side interest. Precigen: The Best Potential Blockbuster You’ve Never Heard Of
• Neutral Sentiment: Q4 earnings materials and call transcripts are available for investors to parse execution details and commercial cadence; management commentary will drive near‑term sentiment. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Q4 beat on EPS (small) but revenue missed estimates — mixed fundamentals that leave room for both upside on commercial execution and downside if sales growth stalls. Precigen Reports Q4 Loss, Lags Revenue Estimates
• Negative Sentiment: After a roughly 145% one‑year surge, some coverage questions valuation and whether near‑term upside is already priced in — pieces asking “Is it too late?” amplify profit‑taking pressure. Is It Too Late To Consider Precigen (PGEN) After Its 145% One Year Surge?
• Negative Sentiment: High trading volume and short‑term pullback risk: elevated turnover after the rally can accelerate declines if upcoming sales data or payer dynamics disappoint — the main near‑term risk for the stock.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.